Modulation of microRNA expression in EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cell lines

被引：0
|
作者：
Haque, Inamul [1 ]
Motes, Hannah [2 ]
Sharma, Mukut [2 ]
Reyes, Emma Borrego-Diaz [2 ]
Godwin, Andrew K. [1 ]
Huang, Chao H. [2 ]
机构：
[1] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[2] Kansas City VA Med Ctr, Kansas City, MO USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-485
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
485
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations
    Wang, Mengzhao
    Xu, Yan
    Huang, Wen-Tsung
    Su, Wu-Chou
    Gao, Bo
    Lee, Chee Khoon
    Fang, Jian
    Zhu, Xuehua
    Yang, Zhenfan
    Jaenne, Pasi A.
    Yang, James Chih-Hsin
    LUNG CANCER, 2025, 199
  • [2] Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer
    Sierra, Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    CLINICAL CANCER RESEARCH, 2012, 18 (03)
  • [3] Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Sierra, J. Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    CANCER RESEARCH, 2012, 72
  • [4] MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
    Chen, Chao-Ju
    Liu, Yu-Peng
    PHARMACEUTICALS, 2021, 14 (02) : 1 - 25
  • [5] Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
    Salvatore Corallo
    Ettore D’Argento
    Antonia Strippoli
    Michele Basso
    Santa Monterisi
    Sabrina Rossi
    Alessandra Cassano
    Carlo M. Barone
    Targeted Oncology, 2017, 12 : 153 - 161
  • [6] Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
    Corallo, Salvatore
    D'Argento, Ettore
    Strippoli, Antonia
    Basso, Michele
    Monterisi, Santa
    Rossi, Sabrina
    Cassano, Alessandra
    Barone, Carlo M.
    TARGETED ONCOLOGY, 2017, 12 (02) : 153 - 161
  • [7] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [8] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
    Joshi, Pooja
    Singh, Anita
    Bisht, Dheeraj
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
  • [9] Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
    Raimbourg, Judith
    Joalland, Marie-Pierre
    Cabart, Mathilde
    de Plater, Ludmilla
    Bouquet, Fanny
    Savina, Ariel
    Decaudin, Didier
    Bennouna, Jaafar
    Vallette, Francois M.
    Lalier, Lisenn
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (08) : 1634 - 1644
  • [10] Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
    Igawa, Satoshi
    Ono, Taihei
    Kasajima, Masashi
    Ishihara, Mikiko
    Hiyoshi, Yasuhiro
    Kusuhara, Seiichiro
    Nishinarita, Noriko
    Fukui, Tomoya
    Kubota, Masaru
    Sasaki, Jiichiro
    Hisashi, Mitsufuji
    Yokoba, Masanori
    Katagiri, Masato
    Naoki, Katsuhiko
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4883 - 4892
12345